First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Timothy BeukelmanGeorge TomlinsonPeter A NigrovicAnne DennosVincent Del GaizoMarian JelinekMary Ellen RiordanLaura E SchanbergShalini MohanErin PfeiferYukiko Kimuranull nullPublished in: Pediatric rheumatology online journal (2022)
Nearly all patients received treatment with biologics during the study period, and 46% of biologic CTP patients did not receive oral GC within the first month of treatment. The majority of patients had favorable short-term clinical outcomes. Increased use of biologics and decreased use of GC may lead to improved outcomes in sJIA.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- juvenile idiopathic arthritis
- peritoneal dialysis
- prognostic factors
- rheumatoid arthritis
- metabolic syndrome
- patient reported outcomes
- high resolution
- combination therapy
- adipose tissue
- insulin resistance
- patient reported
- clinical practice
- disease activity
- simultaneous determination